ReviewActa histochemica et cytochemica2026
Spatial Transcriptomics Meets Histochemistry: Insights from Glioblastoma as a Model System.
Review in Acta histochemica et cytochemica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-resolution spatial transcriptomics has emerged as a powerful approach for linking genome-wide gene expression with preserved tissue architecture, enabling new insights into cellular heterogeneity and microenvironmental organization in complex tissues. In neuropathology, where morphological context is central to disease interpretation, these technologies are particularly appealing. Using glioblastoma multiforme (GBM) as a representative and highly heterogeneous model, this review critically evaluates the strengths and limitations of high-resolution spatial transcriptomic platforms in relation to classical histochemistry and cytochemistry. Illustrative analyses of human GBM tissue demonstrate that spatial transcriptomics robustly captures disease-relevant gene expression patterns and enables comprehensive mapping of key pathological features, including pseudopalisading necrosis, aberrant tumor vasculature, and therapy-resistant tumor niches. When integrated with histopathological observations, spatially resolved transcriptomic data can generate biologically meaningful hypotheses, offering insight into immune suppression, and proliferative signaling networks. These examples underscore the potential of spatial transcriptomics to bridge morphology and molecular biology, thereby expanding the conceptual framework of histopathological research. At the same time, spatial transcriptomic data should not be regarded as a replacement for direct microscopic evaluation. Limitations in morphological fidelity, lack of subcellular resolution, indirect inference of functional states, and reliance on computational interpretation necessitate careful integration with established histochemical and immunohistochemical methods. Without a solid foundation in tissue and cellular morphology, spatial transcriptomic findings may be misinterpreted or overstated. Collectively, this review emphasizes that spatial transcriptomics and histochemistry are complementary approaches, whose effective integration depends critically on rigorous histochemical knowledge to ensure accurate pathological interpretation and translational relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.